Skip to main content

SuperGen brain cancer drug gets orphan status from FDA


WASHINGTON A drug for the most common and malignant brain tumor in adults has received orphan drug status from the Food and Drug Administration, the FDA has announced.

The regulatory agency granted the status to SuperGen’s drug MP-470, a drug for treating glioblastoma multiforme that is in phase I trials. The drug is being tested alone and in combination with chemotherapy in patients with solid tumors.

SuperGen has presented data indicating that the drug is tolerated in humans. The drug has also been effective against several different types of tumors in preclinical testing.

This ad will auto-close in 10 seconds